Efficacy and Safety of Retlirafusp Alfa Plus Bevacizumab and Chemotherapy With or Without Short-Course Radiotherapy in Patients With CRCLM

Efficacy and safety of retlirafusp alfa combined with bevacizumab and chemotherapy with or without short-course radiotherapy in conversion therapy for advanced colorectal cancer liver metastases: an exploratory study.

Trial Details

NCT ID
NCT07728019
Phase
PHASE2
Sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • SCRT
  • Retlirafusp alfa Injection
  • Bevacizumab
  • CAPOX
Locations (sample)
  • Wuhan, Hubei, China|30.58333,114.26667

Key Eligibility Criteria

  • Provide signed written informed consent and voluntarily agree to participate in this study.
  • Age ≥ 18 years and ≤ 75 years.
  • Histologically confirmed colorectal adenocarcinoma.
  • Liver metastasis confirmed by imaging or pathology.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →